Elevated annexin A5 plasma levels in term pregnancies of M2/ANXA5 carriers

Ang, Kai-Cheen; Kathirgamanathan, Sushilnathan; Ch’ng, Ewe Seng; Abdullah, Wan Zaidah; Yusoff, Narazah Mohd; Jahnke, Charlotte; Schmitz, Ralf; Bogdanova, Nadja; Wieacker, P.; Tang, Thean‐Hock; Markoff, Arseni

doi:10.1016/j.thromres.2017.06.008

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 In addition, measured ANXA5 levels in the maternal compartment would not be indicative of raised placental ANXA5 as suggested by a recent study. 37 Since decrease of tissue zinc depots is described in preeclampsia 38 and preconception zinc deficiency disrupts postimplantation fetal and placental development in mice, 39 findings of this study appear largely in line with means for alleviation of observed pathology, although through a different mechanism in this particular model of ANXA5 functional deficiency. Namely, a recent study suggested high angiotensinconverting enzyme activity in preeclamptic placentae to correlate negatively with zinc concentration, 33.3% lower than normal.…”

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

Micromolar Zinc in Annexin A5 Anticoagulation as a Potential Remedy for RPRGL3- Associated Recurrent Pregnancy Loss

Danisik¹,

Bogdanova²,

Markoff³

2019

Reprod. Sci.

Self Cite

View full text Add to dashboard Cite

Deficient expression of the placental anticoagulant annexin A5 (ANXA5) has been associated with thrombophilia-related pregnancy complications and ultimately with recurrent pregnancy loss (RPL). Carrier status of M2/ANXA5 ( RPRGL3), common ANXA5 promoter variant, has been identified as genetic cause of reduced ANXA5 levels and proposed as biomarker for successful anticoagulant treatment of RPL women. A murine model of AnxA5 loss of function displayed characteristic placental pathology and fetal loss that was alleviated through anticoagulant intervention. This study identified an alternative means of supplementing anticoagulation, through elevated ANXA5 expression. Physiological micromolar Zn stimulated ANXA5 transcription, raising ANXA5 protein expression and surface abundance on BeWo and human umbilical vein endothelial cells (HUVEC), thus resulting in prolonged coagulation times. Zn-fed AnxA5 functionally deficient pregnant mice showed a trend to increase litter size when primiparous that grew comparable to wild-type progeny in subsequent pregnancies. Elevated AnxA5 signal upon Zn treatment was confirmed in murine placentae. Micromolar Zn stimulated ANXA5 expression in cell culture directly and alleviated RPL in AnxA5 genetically deficient mice, without notable toxicity effects.

show abstract

Section: Discussionsupporting

confidence: 63%

“…36 In addition, measured ANXA5 levels in the maternal compartment would not be indicative of raised placental ANXA5 as suggested by a recent study. 37…”

Section: Discussionmentioning

confidence: 99%

Micromolar Zinc in Annexin A5 Anticoagulation as a Potential Remedy for RPRGL3- Associated Recurrent Pregnancy Loss

Danisik¹,

Bogdanova²,

Markoff³

2019

Reprod. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…As regards blood plasma specimens, 11 genes, namely ANXA5 , ASPM , CD34 , CDC20 , CDT1 , COL4A5 , COL6A1 , ECT2 , HJURP , MCM2 , and VEGFA , presented with statistically significant differential expression between BCa and healthy individuals. In previous findings, Annexin A5 ( ANXA5 ) plasma levels were investigated as a potential biomarker for asthma diagnosis [ 109 ], pregnant and non-pregnant subjects [ 110 ], as well as for liver cirrhosis and hepatocellular carcinoma [ 111 ]. Abnormal spindle protein homolog ( ASPM ) was detected in circulating tumor cells through single-cell genomic characterization in cancer patients [ 112 ].…”

Section: Discussionmentioning

confidence: 99%

An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer

Sarafidis

Lambrou

Zoumpourlis

et al. 2022

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is one of the most prevalent cancers worldwide and accounts for high morbidity and mortality. This study intended to elucidate potential key biomarkers related to the occurrence, development, and prognosis of BCa through an integrated bioinformatics analysis. In this context, a systematic meta-analysis, integrating 18 microarray gene expression datasets from the GEO repository into a merged meta-dataset, identified 815 robust differentially expressed genes (DEGs). The key hub genes resulted from DEG-based protein–protein interaction and weighted gene co-expression network analyses were screened for their differential expression in urine and blood plasma samples of BCa patients. Subsequently, they were tested for their prognostic value, and a three-gene signature model, including COL3A1, FOXM1, and PLK4, was built. In addition, they were tested for their predictive value regarding muscle-invasive BCa patients’ response to neoadjuvant chemotherapy. A six-gene signature model, including ANXA5, CD44, NCAM1, SPP1, CDCA8, and KIF14, was developed. In conclusion, this study identified nine key biomarker genes, namely ANXA5, CDT1, COL3A1, SPP1, VEGFA, CDCA8, HJURP, TOP2A, and COL6A1, which were differentially expressed in urine or blood of BCa patients, held a prognostic or predictive value, and were immunohistochemically validated. These biomarkers may be of significance as prognostic and therapeutic targets for BCa.

show abstract

Elevated annexin A5 plasma levels in term pregnancies of M2/ANXA5 carriers

Cited by 2 publications

References 10 publications

Micromolar Zinc in Annexin A5 Anticoagulation as a Potential Remedy for RPRGL3- Associated Recurrent Pregnancy Loss

Micromolar Zinc in Annexin A5 Anticoagulation as a Potential Remedy for RPRGL3- Associated Recurrent Pregnancy Loss

An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer

Contact Info

Product

Resources

About